Liraglutide – Mechanism, Uses & Side Effects
Liraglutide is a medication used to treat type 2 diabetes and obesity. It mimics the gut hormone GLP-1, helping to lower blood sugar and reduce appetite.
Things worth knowing about "Liraglutide"
Liraglutide is a medication used to treat type 2 diabetes and obesity. It mimics the gut hormone GLP-1, helping to lower blood sugar and reduce appetite.
What is Liraglutide?
Liraglutide is a synthetic drug belonging to the class of GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonists). It mimics the action of the naturally occurring gut hormone GLP-1, which is released after eating and plays a key role in blood sugar regulation. Liraglutide is marketed under the brand names Victoza (for type 2 diabetes) and Saxenda (for obesity) and is administered as a subcutaneous injection (under the skin).
Indications – When is Liraglutide Used?
Liraglutide is approved for the following conditions:
- Type 2 diabetes mellitus: To improve blood sugar control in adults when diet, exercise, and other antidiabetic medications are insufficient.
- Obesity and overweight: As an adjunct to a reduced-calorie diet and increased physical activity in adults with a BMI of 30 kg/m² or higher, or 27 kg/m² or higher with weight-related comorbidities.
- Cardiovascular risk reduction: In patients with type 2 diabetes and high cardiovascular risk, liraglutide has been shown to significantly reduce the risk of major cardiovascular events such as heart attack and stroke.
Mechanism of Action
Liraglutide selectively binds to the GLP-1 receptor and exerts its effects through several mechanisms:
- Insulin secretion: It stimulates the pancreas to release insulin in a glucose-dependent manner, meaning it only triggers insulin release when blood sugar is elevated, thereby reducing the risk of hypoglycemia.
- Glucagon suppression: Liraglutide inhibits the secretion of glucagon, a hormone that raises blood sugar levels.
- Delayed gastric emptying: The drug slows the rate at which food leaves the stomach, leading to more gradual absorption of nutrients and reduced post-meal blood sugar spikes.
- Appetite suppression: Liraglutide acts on satiety centers in the brain, reducing hunger and overall caloric intake.
Dosage and Administration
Liraglutide is injected subcutaneously once daily, preferably at the same time each day. Injection sites can be rotated between the abdomen, thigh, and upper arm.
- For type 2 diabetes (Victoza): Starting dose of 0.6 mg per day for at least one week, then gradually increased to 1.2 mg or 1.8 mg daily.
- For obesity (Saxenda): Begin at 0.6 mg per day with weekly dose escalations up to the target dose of 3.0 mg daily.
The gradual dose escalation helps minimize gastrointestinal side effects during the initial treatment phase.
Side Effects
Like all medications, liraglutide can cause side effects. The most common include:
- Gastrointestinal (very common): Nausea, vomiting, diarrhea, constipation, and abdominal pain – especially at the start of treatment.
- Hypoglycemia: Rare when used alone, but more frequent in combination with sulfonylureas or insulin.
- Injection site reactions: Redness, itching, or pain at the injection site.
- Increased heart rate: A mild increase in resting heart rate may occur.
- Pancreatitis: In rare cases, inflammation of the pancreas has been reported. Seek medical attention immediately if persistent severe abdominal pain occurs.
Contraindications and Precautions
Liraglutide should not be used in patients with:
- Known hypersensitivity to liraglutide
- Type 1 diabetes or diabetic ketoacidosis
- Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2)
- Severe renal impairment (limited clinical experience)
Liraglutide should not be used during pregnancy or breastfeeding.
Clinical Evidence
The efficacy and safety of liraglutide have been demonstrated in large-scale clinical trials. The LEADER trial showed that liraglutide significantly reduced the rate of major adverse cardiovascular events in patients with type 2 diabetes and high cardiovascular risk. The SCALE trial confirmed significant and sustained weight loss in the treatment of obesity.
References
- Marso SP et al. - Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER Trial). New England Journal of Medicine, 2016; 375:311-322.
- Pi-Sunyer X et al. - A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). New England Journal of Medicine, 2015; 373:11-22.
- European Medicines Agency (EMA) - Product Information for Victoza and Saxenda. EMA, 2023. Available at: www.ema.europa.eu
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, probiotic lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryTransference
Self-efficacy
Somatization
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Liraglutide-en